CABA (Cabaletta Bio) Beta: 3.0645 (As of Jun. 25, 2026)


CABA Cabaletta Bio Inc CABA
34 GF Score
Price $3.04
! 1 Warning Sign
View Full Analysis

What is Cabaletta Bio Beta?

Cabaletta Bio CABA +0.33% 34 Beta is 3.0645 as of Jun. 25, 2026. GuruFocus rates CABA with a GF Score™ of 34/100. The stock has 1 warning sign investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-25), Cabaletta Bio's Beta is 3.0645.


Cabaletta Bio  (NAS:CABA) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Cabaletta Bio Beta Related Terms


Cabaletta Bio Beta Historical Data

* Premium members only.

The historical data trend for Cabaletta Bio's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cabaletta Bio Beta Chart

Cabaletta Bio Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only 0.00 2.46 3.13 3.76 3.80

Cabaletta Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.79 3.87 4.28 3.80 3.09

CABA vs DNA, CADL, CLYM: Beta Comparison

For the Biotechnology subindustry, Cabaletta Bio's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cabaletta Bio Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cabaletta Bio's Beta distribution charts can be found below:

* The bar in red indicates where Cabaletta Bio's Beta falls into.


CABA
34GF Score
Cabaletta Bio Inc CABA
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cabaletta Bio Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 3.0645 mean?
Cabaletta Bio (CABA) has a Beta of 3.0645 as of Jun. 25, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Cabaletta Bio and its competitors.
Is Cabaletta Bio's Beta too high?
Cabaletta Bio's current Beta is 3.0645. Overall, Cabaletta Bio has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Cabaletta Bio's Beta compare to DNA and CADL?
Cabaletta Bio's Beta of 3.0645 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Cabaletta Bio and its competitors. Cabaletta Bio's current Beta is 3.0645. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cabaletta Bio stock overvalued right now?
Cabaletta Bio (CABA) has a current Beta of 3.0645. The current Beta is 3.0645. Cabaletta Bio's overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Cabaletta Bio (CABA), the current Beta is 3.0645 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cabaletta Bio Business Description

Other Exchanges CABA:Mexico
Address 2929 Arch Street, Suite 600, Philadelphia, PA, USA, 19104
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
34GF Score

Get the complete analysis for CABA

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.04
Price